| Date | Time | Source | | | 03/19/2010 | 11:19AM | MWUS | Abraham, Fruchter & Twersky, LLP Announces Filing of a Class Action Lawsuit Against AMAG Pharmaceuticals, Inc.
Abraham, Fruchter & Twersky, LLP filed a class action lawsuit in the United States District Court for the District of Massachusetts (Case No. 10 Civ. 10470) on behalf of purchasers of the common stock of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG) in the Company's secondary public offering ("Secondary... More...>> |
| 03/16/2010 | 9:26AM | BW | AMAG Pharmaceuticals, Inc. Announces Data Presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that one abstract has been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting being held April 13-17, 2010 in Orlando, FL. The full abstract can now be viewed on the NKF website at http://www.kidney.org/news/meetings/clinical/index.cfm... More...>> |
| 03/02/2010 | 4:25PM | BW | AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 30th Annual Healthcare Conference
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company at the Cowen and Company 30th Annual Healthcare Conference on March 9 at 3:45 p.m. ET. The Conference is being held March 8-11, 2010 in Boston, MA. A live webcast of the presentation... More...>> |
| 03/01/2010 | 7:00AM | BW | AMAG Pharmaceuticals Announces Fourth Quarter and Year End 2009 Financial Results
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results... More...>> |
| 02/22/2010 | 4:10PM | BW | AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Fourth Quarter & Year Ended December ...
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009 before the U.S. financial markets open on March 1, 2010. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET... More...>> |
| 02/05/2010 | 5:21PM | DJN | AMAG Pharma:Rate Of Feraheme Serious Side Effects As Expected
DOW JONES NEWSWIRES AMAG Pharmaceuticals Inc. (AMAG) said 40 serious side effects have been reported since the commercial launch of its Feraheme anemia treatment in July, 0.1% of the estimated 35,000 times patients have taken the drug. Shares gained 4.5% to $39.45 in after-hours trading as AMAG said that rate was consistent... More...>> |
| 02/05/2010 | 4:17PM | BW | AMAG Pharmaceuticals Provides Feraheme® Safety Update
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection... More...>> |
| 01/20/2010 | 7:30PM | BW | AMAG Pharmaceuticals Announces Pricing of Public Offering of 3,600,000 Shares of Common Stock
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $48.25 per share. The number of shares reflects an increase of 600,000 shares over the number of shares anticipated to be sold as previously announced... More...>> |
| 01/19/2010 | 4:47PM | BW | AMAG Pharmaceuticals Announces Proposed Offering of 3,000,000 Shares of Common Stock
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it is offering to sell 3,000,000 shares of its common stock in an underwritten public offering. It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 450,000 shares. Morgan Stanley & Co. Incorporated, J.P... More...>> |
| 01/10/2010 | 7:30PM | BW | AMAG Pharmaceuticals Announces Preliminary Feraheme® Fourth Quarter 2009 Net Product Revenues Estimates
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts... More...>> |
| 01/08/2010 | 4:12AM | PRNUS | 3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
3SBio Inc. (NASDAQ:SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for... More...>> |
| 01/05/2010 | 9:07AM | BW | AMAG Pharmaceuticals, Inc. to Present at the 28th Annual J.P. Morgan Healthcare Conference
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company and provide an update on the commercial launch of Feraheme® (ferumoxytol) Injection at the 28th Annual J.P. Morgan Healthcare Conference on January 11, 2010 at 11:00 a.m. P.T... More...>> |
| 12/17/2009 | 4:05PM | BW | AMAG Pharmaceuticals, Inc. Announces Appointment of Lesley Russell to Board of Directors
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Dr. Lesley Russell, Executive Vice President and Chief Medical Officer of Cephalon, has been elected to AMAG’s Board of Directors, effective immediately. Additionally, the Company announced that Mark Skaletsky has resigned from AMAG’s Board of Directors... More...>> |
| 12/08/2009 | 4:05PM | BW | AMAG Pharmaceuticals, Inc. to Present at the Deutsche Bank 2009 Biotech Boston Confab Conference
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that David Arkowitz, Executive Vice President, Chief Financial Officer and Chief Business Officer, and Lou Brenner, Senior Vice President, will present an overview of the Company at the Deutsche Bank 2009 Biotech Boston Confab Conference on December 15, 2009 at... More...>> |
| 11/12/2009 | 4:15PM | BW | AMAG Pharmaceuticals, Inc. to Participate in the Lazard Capital Markets 6th Annual Healthcare Conference
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that David Arkowitz, Executive Vice President, Chief Financial Officer and Chief Business Officer will present an overview of the Company at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18 at 2:15 p.m. ET. The conference is... More...>> |
| 10/29/2009 | 7:45AM | BW | AMAG Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2009
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third... More...>> |
| 10/21/2009 | 8:30AM | BW | AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2009
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the third quarter ended September 30, 2009 before the U.S. financial markets open on October 29, 2009. The announcement will be followed by a conference call at 8:30 a.m. ET during which management will... More...>> |
| 10/07/2009 | 9:05AM | BW | AMAG Pharmaceuticals, Inc. Announces Data Presentations at the American Society of Nephrology (ASN) Renal Week Meeting
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that three abstracts have been accepted for presentation at the American Society of Nephrology (ASN) Renal Week meeting being held October 27-November 1, 2009 in San Diego, CA. Full abstracts can now be viewed on the ASN website at www.asn-online.org. The three... More...>> |
| 09/10/2009 | 4:05PM | BW | AMAG Pharmaceuticals, Inc. to Provide Company Update at the Morgan Stanley Global Healthcare Unplugged Conference
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will provide an update on the Company and answer questions at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14 at 9:45 a.m. ET. The conference is being held on September... More...>> |
| 09/04/2009 | 4:05PM | BW | AMAG Pharmaceuticals Adopts Shareholder Rights Plan
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its Board of Directors has adopted a Shareholder Rights Plan (“Rights Plan”) under which all shareholders of record as of September 17, 2009 will receive rights to purchase shares of a new series of Preferred Stock. The Rights Plan is designed to ensure... More...>> |
|